{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:51:38Z","timestamp":1777949498507,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-026-03794-x","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:44:44Z","timestamp":1774403084000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of serious infections, myocardial infarction or stroke, venous thromboembolic events, and malignancy in patients with psoriatic arthritis treated with tofacitinib compared with biologic treatments in the United States"],"prefix":"10.1186","volume":"28","author":[{"given":"Marina","family":"Magrey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8351-4626","authenticated-orcid":false,"given":"Milena A.","family":"Gianfrancesco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Fallon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"Yndestad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Vranic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You-Li","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Gruben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey R.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"10","key":"3794_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957\u201370.","journal-title":"N Engl J Med"},{"issue":"10136","key":"3794_CR2","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","volume":"391","author":"DJ Veale","year":"2018","unstructured":"Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273\u201384.","journal-title":"Lancet"},{"issue":"12","key":"3794_CR3","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1002\/acr.22404","volume":"66","author":"P Helliwell","year":"2014","unstructured":"Helliwell P, Coates L, Chandran V, Gladman D, de Wit M, FitzGerald O, Kavanaugh A, Strand V, Mease PJ, Boehncke W-H, et al. Qualifying unmet needs and improving standards of care in psoriatic arthritis. Arthritis Care Res (Hoboken). 2014;66(12):1759\u201366.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"3794_CR4","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, Boehncke WH, Esbensen BA, McInnes IB, McGonagle D, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706\u201319.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3794_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/acr.23789","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, et al. Special article: 2018 American college of rheumatology\/national psoriasis foundation guideline for the treatment of psoriatic arthritis. Arthritis Care Res (Hoboken). 2019;71(1):2\u201329.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3794_CR6","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, Chau J, Eder L, Fern\u00e1ndez-\u00c1vila DG, FitzGerald O, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18:465\u201379.","journal-title":"Nat Rev Rheumatol"},{"issue":"16","key":"3794_CR7","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, Ci\u00e9slak D, Graham D, Wang C, Menon S, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377(16):1537\u201350.","journal-title":"N Engl J Med"},{"issue":"16","key":"3794_CR8","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377(16):1525\u201336.","journal-title":"N Engl J Med"},{"issue":"4","key":"3794_CR9","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S2665-9913(21)00010-2","volume":"3","author":"P Nash","year":"2021","unstructured":"Nash P, Coates LC, Fleishaker D, Kivitz AJ, Mease PJ, Gladman DD, FitzGerald O, Wang C, Wu J, Hsu M, et al. Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study. Lancet Rheumatol. 2021;3(4):e270\u2013283.","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"3794_CR10","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, Germino R, Menon S, Sun Y, Wang C, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326.","journal-title":"N Engl J Med"},{"issue":"7","key":"3794_CR11","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1136\/ard-2022-223715","volume":"82","author":"LE Kristensen","year":"2023","unstructured":"Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023;82(7):901\u201310.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3794_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/ard-2022-222259","volume":"82","author":"C Charles-Schoeman","year":"2023","unstructured":"Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, Koch GG, Vranic I, Wu J, Wang C, et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2023;82(1):119\u201329.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"3794_CR13","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40744-024-00662-5","volume":"11","author":"LE Kristensen","year":"2024","unstructured":"Kristensen LE, Deodhar A, Leung YY, Vranic I, Mortezavi M, Fallon L, Yndestad A, Kinch CD, Gladman DD. Risk stratification of patients with psoriatic arthritis and ankylosing spondylitis for treatment with tofacitinib: a review of current clinical data. Rheumatol Ther. 2024;11(3):487\u201399.","journal-title":"Rheumatol Ther"},{"key":"3794_CR14","doi-asserted-by":"publisher","first-page":"1759720X2211499","DOI":"10.1177\/1759720X221149965","volume":"15","author":"LE Kristensen","year":"2023","unstructured":"Kristensen LE, Strober B, Poddubnyy D, Leung Y-Y, Jo H, Kwok K, Vranic I, Fleishaker DL, Fallon L, Yndestad A, et al. Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib. Ther Adv Musculoskelet Dis. 2023;15:1759720X221149965.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"11","key":"3794_CR15","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","volume":"177","author":"H Wadstr\u00f6m","year":"2017","unstructured":"Wadstr\u00f6m H, Frisell T, Askling J, Anti-Rheumatic Therapy in Sweden Study Group. Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden. JAMA Intern Med. 2017;177(11):1605\u201312.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"3794_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/art.30653","volume":"64","author":"DH Solomon","year":"2012","unstructured":"Solomon DH, Mercer E, Kavanaugh A. Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. Arthritis Rheum. 2012;64(1):21\u201332.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"3794_CR17","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"3794_CR18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s40744-023-00631-4","volume":"11","author":"PJ Mease","year":"2024","unstructured":"Mease PJ, Young P, Fallon L, Mundyat R, Dina O, Blachley T, Middaugh N, Ogdie A. Effectiveness of tofacitinib in patients initiating therapy for psoriatic arthritis: results from the CorEvitas Psoriatic Arthritis\/Spondyloarthritis Registry. Rheumatol Ther. 2024;11(2):313\u201329.","journal-title":"Rheumatol Ther"},{"issue":"6","key":"3794_CR19","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1007\/s12325-022-02084-7","volume":"39","author":"PJ Mease","year":"2022","unstructured":"Mease PJ, Young P, Gruben D, Fallon L, Germino R, Kavanaugh A. Early real-world experience of tofacitinib for psoriatic arthritis: data from a United States healthcare claims database. Adv Ther. 2022;39(6):2932\u201345.","journal-title":"Adv Ther"},{"issue":"2","key":"3794_CR20","doi-asserted-by":"publisher","first-page":"e001595","DOI":"10.1136\/rmdopen-2021-001595","volume":"7","author":"GR Burmester","year":"2021","unstructured":"Burmester GR, Nash P, Sands BE, Papp K, Stockert L, Jones TV, Tan H, Madsen A, Valdez H, Cohen SB. Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure. RMD Open. 2021;7(2):e001595.","journal-title":"RMD Open"},{"issue":"8","key":"3794_CR21","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1002\/art.42846","volume":"76","author":"C Charles-Schoeman","year":"2024","unstructured":"Charles-Schoeman C, Fleischmann R, Mysler E, Greenwald M, Ytterberg SR, Koch GG, Bhatt DL, Wang C, Mikuls TR, Chen A-, et al. Risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors in cardiovascular risk-enriched rheumatoid arthritis patients. Arthritis Rheumatol. 2024;76(8):1218\u201329.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"3794_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/rheumatology\/keab294","volume":"61","author":"RJ Desai","year":"2021","unstructured":"Desai RJ, Pawar A, Khosrow-Khavar F, Weinblatt ME, Kim SC. Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study. Rheumatology (Oxford). 2021;61(1):121\u201330.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"3794_CR23","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/art.40798","volume":"71","author":"RJ Desai","year":"2019","unstructured":"Desai RJ, Pawar A, Weinblatt ME, Kim SC. Comparative risk of venous thromboembolism in rheumatoid arthritis patients receiving tofacitinib versus those receiving tumor necrosis factor inhibitors: an observational cohort study. Arthritis Rheumatol. 2019;71(6):892\u2013900.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"3794_CR24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/fcp.12326","volume":"32","author":"M Prat","year":"2018","unstructured":"Prat M, Derumeaux H, Sailler L, Lapeyre-Mestre M, Moulis G. Positive predictive values of peripheral arterial and venous thrombosis codes in French hospital database. Fundam Clin Pharmacol. 2018;32(1):108\u201313.","journal-title":"Fundam Clin Pharmacol"},{"issue":"11","key":"3794_CR25","doi-asserted-by":"publisher","first-page":"e008864","DOI":"10.1136\/bmjopen-2015-008864","volume":"5","author":"A Abdul Sultan","year":"2015","unstructured":"Abdul Sultan A, West J, Stephansson O, Grainge MJ, Tata LJ, Fleming KM, Humes D, Ludvigsson JF. Defining venous thromboembolism and measuring its incidence using Swedish health registries: a nationwide pregnancy cohort study. BMJ Open. 2015;5(11):e008864.","journal-title":"BMJ Open"},{"issue":"2","key":"3794_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/03009742.2021.2001907","volume":"52","author":"V Molander","year":"2023","unstructured":"Molander V, Bower H, Askling J. Validation and characterization of venous thromboembolism diagnoses in the Swedish national patient register among patients with rheumatoid arthritis. Scand J Rheumatol. 2023;52(2):111\u20137.","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"3794_CR27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11239-019-01885-y","volume":"48","author":"K Lawrence","year":"2019","unstructured":"Lawrence K, Joos C, Jones AE, Johnson SA, Witt DM. Assessing the accuracy of ICD-10 codes for identifying acute thromboembolic events among patients receiving anticoagulation therapy. J Thromb Thrombolysis. 2019;48(2):181\u20136.","journal-title":"J Thromb Thrombolysis"},{"key":"3794_CR28","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.2147\/CLEP.S177058","volume":"10","author":"L \u00d6hman","year":"2018","unstructured":"\u00d6hman L, Johansson M, Jansson JH, Lind M, Johansson L. Positive predictive value and misclassification of diagnosis of pulmonary embolism and deep vein thrombosis in Swedish patient registries. Clin Epidemiol. 2018;10:1215\u201321.","journal-title":"Clin Epidemiol"},{"key":"3794_CR29","doi-asserted-by":"publisher","first-page":"671","DOI":"10.2147\/CLEP.S402360","volume":"15","author":"S Kim","year":"2023","unstructured":"Kim S, Martin C, White J, Carlyle M, Bui B, Gao S, Salinas CA. Validation of an algorithm to identify venous thromboembolism in health insurance claims data among patients with rheumatoid arthritis. Clin Epidemiol. 2023;15:671\u201382.","journal-title":"Clin Epidemiol"},{"issue":"9","key":"3794_CR30","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.7326\/M22-1460","volume":"175","author":"LM DeTora","year":"2022","unstructured":"DeTora LM, Toroser D, Sykes A, Vanderlinden C, Plunkett FJ, Lane T, Hanekamp E, Dormer L, DiBiasi F, Bridges D, et al. Good Publication Practice (GPP) guidelines for company-sponsored biomedical research: 2022 update. Ann Intern Med. 2022;175(9):1298\u2013304.","journal-title":"Ann Intern Med"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-026-03794-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03794-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03794-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:09:08Z","timestamp":1777853348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-026-03794-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3794"],"URL":"https:\/\/doi.org\/10.1186\/s13075-026-03794-x","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this study utilized anonymized structured data that, in accordance with relevant legal standards, did not include information subject to privacy regulations, informed patient consent was not required. Institutional Review Board and Independent Ethics Committee review were also not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MM has acted as a consultant for AbbVie, Eli Lilly, Johnson & Johnson, Novartis, Pfizer Inc, and UCB, and has received grants\/research support from Amgen and Bristol Myers Squibb. MAG, LF, AY, IV, Y-LL, and DG are employees and stockholders of Pfizer Inc. YW is an employee of Komodo Health. Komodo Health received compensation from Pfizer Inc for analytics services. JRC has acted as a consultant for, and has received grant support from, Pfizer Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"103"}}